#United States #San Antonio #Caris Life Sciences #Breast Cancer #SABCS

Caris Life Sciences at the 2025 San Antonio Breast Cancer Symposium

Caris Life Sciences® (NASDAQ: CAI), a forerunner in patient-centered AI TechBio innovations, proudly announced its intention to present 19 significant research studies at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place from December 9-12, 2025. This prestigious event will serve as a global platform for researchers and clinicians to share insights and advancements in breast cancer treatment and patient care.

Among the studies being showcased, Caris, in collaboration with esteemed cancer centers linked to the Caris Precision Oncology Alliance™ (Caris POA), will delve into a variety of breast cancer subtypes. These include HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, as well as studies focused on male and metastatic breast cancer cases. By harnessing the power of multi-omics profiling, these investigations exemplify how comprehensive data analysis can drive precision oncology forward, ultimately leading to enhanced patient outcomes.

Dr. George W. Sledge, Jr., Caris' Executive Vice President and Chief Medical Officer, emphasized the importance of this symposium, stating, "SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris' multi-omic tumor profiling is helping define molecularly distinct patient groups." He added that the integration of whole-exome and whole-transcriptome sequencing, coupled with immunohistochemistry (IHC) profiling and AI signatures, is revolutionizing our understanding of therapeutic resistance and guiding personalized cancer care approaches.

One highlight includes an oral presentation on the potential of integrating multimodal AI models to forecast breast cancer recurrence risks. This pivotal study, titled 'Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx,' will take place during the general session on December 10, 2025. This innovative approach aims to bridge the gap between imaging data and clinical insights, providing a comprehensive understanding of patient needs.

Moreover, a rapid oral presentation will focus on advanced deep learning models that have been trained within the context of NSABP B-42 and validated in TAILORx for predicting late distant recurrence risk specifically in HR+ early breast cancer patients. This session promises to shed light on new methodologies in cancer recurrence prediction, further supporting the vital importance of personalized treatment plans.

Alongside these landmark presentations, Caris will feature spotlight posters that tackle current challenges in breast cancer therapies. For instance, 'Personalized Acquired CDK4/6i Resistance Associations with Baseline Characteristics Like Obesity in Real-World Clinical-Multiomics Data' and 'Overcoming ADC Resistance Payload Diversification as a Strategy for Sequential Therapy', will highlight recent findings that speak to the complexities of treatment interactions and patient characteristics.

Furthermore, the investigation titled 'The Genomic, Transcriptomic, and Immune Characterization of Metastatic Lobular Breast Cancer' will provide an in-depth analysis of this specific breast cancer subtype, looking to unravel crucial insights that can lead to improved clinical practices.

In total, Caris will feature more than 40 collaborating institutions throughout the conference, emphasizing the extensive network committed to advancing cancer research and precision medicine. As part of the multifaceted endeavors of the Caris Precision Oncology Alliance, these partnerships aim to elevate standards in molecular testing and optimize treatment frameworks across the globe.

As a pioneer in the field of precision medicine, Caris Life Sciences continues to demonstrate its commitment to improving healthcare through innovative solutions. By integrating the latest advancements in AI and molecular profiling techniques, Caris is not only redefining cancer treatment paradigms but is also paving the way for future discoveries that can revolutionize how clinicians approach patient care.

With a central aim to enhance patient outcomes through precision oncology, Caris stands at the forefront of this transformative era in cancer care. The insights shared at the SABCS are expected to catalyze dialogue and collaboration among specialists, illustrating the critical role of next-generation technologies in the ongoing fight against breast cancer.

For additional details on the studies presented, Caris will have resources available at their booth #209 during the symposium, and full abstracts will be published on their official website following the event.